Utilizing pre-therapy clinical schema and initial CT changes to predict progression-free survival in patients with metastatic renal cell carcinoma on VEGF-targeted therapy: A preliminary analysis

Urologic Oncology: Seminars and Original Investigations

Volumn 31, Issue 7, 2013, Pages 1283-1291

  Smith, Andrew D ^a   Shah, Shetal N ^b   Rini, Brian I ^c   Lieber, Michael L ^b   Remer, Erick M ^b  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

Metastatic renal cell carcinoma; Predicting outcome; Response evaluation

Indexed keywords

SORAFENIB; SUNITINIB; VASCULOTROPIN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER PATIENT; CANCER RISK; CANCER THERAPY; CLINICAL FEATURE; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED TOMOGRAPHY; DISEASE SPECIFIC SURVIVAL; FEMALE; HEALTH CARE COST; HUMAN; KARNOFSKY PERFORMANCE STATUS; KIDNEY METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PATIENT COUNSELING; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TREATMENT RESPONSE;

METASTATIC RENAL CELL CARCINOMA; PREDICTING OUTCOME; RESPONSE EVALUATION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INDOLES; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; NIACINAMIDE; OUTCOME ASSESSMENT (HEALTH CARE); PHENYLUREA COMPOUNDS; PROGNOSIS; PYRROLES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TOMOGRAPHY, X-RAY COMPUTED; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84884674930     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2011.08.010     Document Type: Article

References (21)

1. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon α in metastatic renal-cell carcinoma. N Engl J Med 2007, 356:115-124.
2. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356:125-134.
3. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009, 27:3312-3318.
4. Motzer R.J., Hutson T.E., Tomczak P., et al. Overall survival and updated results for sunitinib compared with interferon α in patients with metastatic renal cell carcinoma. J Clin Oncol 2009, 27:3584-3590.
5. Motzer R.J., Bacik J., Murphy B.A., et al. Inteferon α as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002, 20:289-296.
6. Choueiri T.K., Garcia J.A., Elson P., et al. Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer 2007, 110:543-550.
7. Heng D.Y., Xie W., Regan M.M., et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: Results from a large, multicenter study. J Clin Oncol 2009, 27:5794-5799.
8. Mekhail T.M., Abou-Jawde R.M., BouMerhi G., et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 2005, 23:832-841.
9. Motzer R.J., Bukowski R.M., Figlin R.A., et al. Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma. Cancer 2008, 113:1552-1558.
10. Thiam R., Fournier L.S., Trinquart L., et al. Optimizing the size variation threshold for the CT evaluation of response in metastatic renal cell carcinoma treated with sunitinib. Annals of Oncology 2010, 21:936-941.
11. Han K.S., Jung D.C., Choi H.J., et al. Pretreatment assessment of tumor enhancement on contrast-enhanced computed tomography as a potential predictor of treatment outcome in metastatic renal cell carcinoma patients receiving anti-angiogenic therapy. Cancer 2010, 116:2332-2342.
12. van der Veldt A.A., Meijerink M.R., van den Eertwegh A.J., et al. Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. Br J Cancer 2010, 102:803-809.
13. Smith A.D., Lieber M.L., Shah S.N. Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: Importance of size and attenuation on contrast enhanced CT. Am J Roentgenol 2010, 194:157-165.
14. Smith A.D., Shah S.N., Rini B.I., et al. Morphology, Attenuation, Size, and Structure (MASS) criteria: Assessing response and predicting clinical outcome in metastatic renal cell carcinoma on anti-angiogenic targeted therapy. Am J Roentgenol 2010, 194:1470-1478.
15. Nathan P.D., Vinayan A., Stott D., et al. CT response assessment combining reduction in both size and arterial phase density correlates with time to progression in metastatic renal cancer patients treated with targeted therapies. Cancer Biol Ther 2010, 9:15-19.
16. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216.
17. Benjamin R.S., Choi H., Macapinlac H.A., et al. We should desist using RECIST, at least in GIST. J Clin Oncol 2007, 25:1760-1764.
18. Choi H., Charnsangavej C., Faria S.C. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: Proposal of new computed tomography response criteria. J Clin Oncol 2007, 25:1753-1759.
19. Bamias A., Karadimou A., Lampaki S., et al. Prognostic stratification of patients with advanced renal cell carcinoma treated with sunitinib: Comparison with the Memorial Sloan-Kettering prognostic factors model. BMC Cancer 2010, 10:45-56.
20. Motzer R.J., Michaelson M.D., Redman B.G., et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006, 24:16-24.
21. Baccala A., Hedgepeth R., Kaouk J., et al. Pathological evidence of necrosis in recurrent renal mass following treatment with sunitinib. Int J Urol 2007, 14:1095-1097.